Journal Image
Current Alzheimer Research
ISSN (Print): 1567-2050
ISSN (Online): 1875-5828
DOI: 10.2174/15672050113106660167

The prediction of response to Galantamine treatment in Patients with mild to moderate Alzheimer’s Disease

Author(s): Takashi Ohnishi, Yojiro Sakiyama, Yuichi Okuri, Yuji Kimura, Nami Sugiyama, Takayuki Saito, Masayoshi Takahashi and Takumi Kobayashi
Pages 110-118 (9)
The prediction of efficacy in long-term treatment of acetylcholinesterase inhibitors (AChEIs) is a major clinical issue, although no consistently strong predictive factors have emerged thus far. The present analyses aimed to identify factors for predicting long-term outcome of galantamine treatment. Analyses were conducted with data from a 24 weeks randomized, double-blind, placebo controlled trial to evaluate the efficacy and the safety of galantamine in the treatment of 303 patients with mild to moderate AD. Patients were divided into responders (4 or more point improvement of ADAScog scores at 24 weeks of treatment) and non-responders. We explored whether patients’ background (e.g. sex, age, and duration of disease) and scores of cognitive scales at early stage, are relevant to the long-term response to AChEIs. Predictive values were estimated by the logistic regression model. The responder rate was 31.7%. We found that changes in scores of ADAS-J cog subscales between week 4 and baseline, especially word recognition, can be a good variable to predict subsequent response to galantamine, with approximately 75% of predictive performance. Characteristics of patients, including demographic characteristics, severity of disease and neuropsychological features before treatment were poorly predictive. The present study indicate that initial response to galantamine administration in patients with mild to moderate AD seems to be a reliable predictor of response of consequent galantamine treatment. Patients who show improvement of episodic memory function during the first 4 weeks of galantamine administration may be likely to particularly benefit from galantamine treatment.
Acetylcholinesterase inhibitor, Alzheimer's disease, Alzheimer’s disease assessment scale-cognitive subscale (ADAS-cog), galantamine, pharmacotherapy, responders.
Scientific Affairs Division, CNS Science Department, Janssen Pharmaceutical K.K., 5-2, Nishi-kanda 3-chome, Chiyoda-ku, Tokyo 101-0065, Japan.